Nav: Home

Possible treatment for breast cancer patients could roll out to clinical trial immediately

March 10, 2020

A worldwide collaborative study led by scientists at the University of Sussex has proposed a new treatment strategy for patients with a rare but aggressive subtype of cancer known as triple negative breast cancer.

The treatment targets healthy cells using drugs that are already available and currently in use for patients with leukaemia and lymphoma.

Around 15% of breast cancer cases are diagnosed as triple negative breast cancer - a form of solid cancer where cells don't have receptors for the oestrogen (ΕRα) and progesterone hormones (PR), or a protein known as HER2. Current treatments involve surgery or chemotherapy, however prognosis still remains poor.

A new study led by Georgios Giamas, Professor of Cancer Cell Signalling at the University of Sussex, has provided strong evidence for the development of a new type of treatment to halt progression of the disease by using existing drugs to target the surrounding healthy tissues of cancerous cells, known as fibroblasts.

Prof Giamas said: "Cancer is a systemic disease so instead of only focusing on cancer cells to find a cure, sometimes we need to step back and look at the bigger picture known as the tumour microenvironment'. This means looking at the surrounding cell types - the 'normal cells' - that can actually contribute either positively or negatively to the progression of the disease."

Using samples from triple negative breast cancer patients, researchers found that overall survival was markedly worse when levels of the protein PIK3Cδ were high in surrounding healthy tissue. Interestingly, this was not the case for the other two subtypes of breast cancer(ΕRα+ and HER2+).

PIK3Cδ inhibitors were tested in two different breast cancer mouse models with results showing a reduction in tumour growth. As PIK3Cδ is mainly expressed in white blood cells, scientists believe that these drugs acted predominantly on the immune system. The findings suggest that if treatments could control levels of PIK3Cδ in the surrounding normal cells, then survival outcomes for patients would improve.

Prof Giamas said: "The lack of effective therapies for triple negative breast cancer is well-established, despite the emergence of approaches like immunotherapy.

"Our results suggest that repurposing already available drugs which act as inhibitors for PIK3Cδ could stop the progression of the disease. As the drugs are already available and FDA approved, clinical trials could begin immediately to further investigate the use of these inhibitors for triple negative breast cancer treatment."

Dr. Teresa Gagliano, first author of the study and currently Senior Scientist at the University of Zurich, said: "If we had focused only on the cancer cells, we would have never identified PIK3Cδ, and the possibility of an alternative therapy. Sometimes it's fundamental to think outside the box."

The study, funded by Action Against Cancer, involved scientists from across three continents and six different countries and was published in the Journal of Clinical Investigation.

The findings will be of interest to oncologists who may decide to take this forward to clinical trial, if the Medicines and Healthcare products Regulatory Agency (MHRA) review and authorise the drug.

University of Sussex

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at